Carmel Capital Partners LLC Has $2.35 Million Stock Position in IQVIA Holdings Inc. $IQV

Key Points

• Carmel Capital Partners LLC increased its stake in IQVIA Holdings Inc. by 38.2%, now owning 14,878 shares valued at approximately $2.35 million.
• Brokerages are optimistic, with Barclays and UBS raising their price targets for IQVIA shares to $200 and $225, respectively.
• Insider selling occurred recently, with significant transactions including Keriann Cherofsky selling 549 shares for about $105,150.

Carmel Capital Partners LLC boosted its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 38.2% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 14,878 shares of the medical research company's stock after purchasing an additional 4,115 shares during the period. IQVIA comprises 0.8% of Carmel Capital Partners LLC's holdings, making the stock its 29th largest position. Carmel Capital Partners LLC's holdings in IQVIA were worth $2,345,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of the company. Clal Insurance Enterprises Holdings Ltd lifted its position in IQVIA by 436.7% during the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company's stock worth $28,000 after acquiring an additional 131 shares during the last quarter. Golden State Wealth Management LLC lifted its position in IQVIA by 295.5% during the first quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock worth $31,000 after acquiring an additional 130 shares during the last quarter. AllSquare Wealth Management LLC acquired a new stake in IQVIA during the first quarter worth approximately $33,000. Trust Co. of Toledo NA OH acquired a new stake in IQVIA during the second quarter worth approximately $39,000. Finally, J.Safra Asset Management Corp lifted its position in IQVIA by 208.6% during the second quarter. J.Safra Asset Management Corp now owns 250 shares of the medical research company's stock worth $39,000 after acquiring an additional 169 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have issued reports on IQV. Barclays raised their price objective on shares of IQVIA from $185.00 to $200.00 and gave the stock an "equal weight" rating in a research report on Thursday, October 2nd. Redburn Partners set a $214.00 price objective on shares of IQVIA in a research report on Wednesday, September 3rd. UBS Group raised their target price on shares of IQVIA from $185.00 to $225.00 and gave the stock a "buy" rating in a report on Wednesday, July 23rd. Hsbc Global Res raised shares of IQVIA from a "hold" rating to a "strong-buy" rating in a report on Thursday, October 9th. Finally, William Blair reaffirmed an "outperform" rating on shares of IQVIA in a report on Wednesday, July 23rd. One analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and five have given a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $234.57.

Insider Buying and Selling

In related news, insider Keriann Cherofsky sold 549 shares of IQVIA stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total value of $105,149.97. Following the transaction, the insider directly owned 2,910 shares of the company's stock, valued at $557,352.30. This trade represents a 15.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Eric Sherbet sold 5,800 shares of the business's stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the sale, the insider directly owned 27,178 shares in the company, valued at approximately $5,165,178.90. The trade was a 17.59% decrease in their position. The disclosure for this sale can be found here. Company insiders own 1.60% of the company's stock.

IQVIA Stock Performance

Shares of NYSE:IQV opened at $204.51 on Friday. The company's 50 day simple moving average is $191.41 and its 200 day simple moving average is $169.23. The stock has a market capitalization of $34.77 billion, a price-to-earnings ratio of 29.60, a price-to-earnings-growth ratio of 2.26 and a beta of 1.32. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $237.21.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.77 by $0.04. The business had revenue of $4.02 billion for the quarter, compared to analysts' expectations of $3.96 billion. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The firm's quarterly revenue was up 5.3% compared to the same quarter last year. During the same period last year, the firm posted $2.64 earnings per share. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. As a group, research analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.